Virtual Library

Start Your Search

Weini Qiu



Author of

  • +

    P2.14 - Targeted Therapy (ID 183)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.14-01 - Real World Treatment Outcomes in Chinese Patients with RET-Rearranged Lung Cancer (ID 2471)

      10:15 - 18:15  |  Author(s): Weini Qiu

      • Abstract
      • Slides

      Background

      One global, multicenter study has identified available multi-targeted kinase inhibitors has limited activity in patients with RET-rearranged non-small-cell lung cancer (NSCLC). However, there is limited molecular and clinical data with RET-rearranged NSCLC in China.

      Method

      Retrospective real-world analysis of clinical, molecular, and treatment outcome of a web-based patient registry and hospital chart review in China.

      Result

      By 28/03/2019, 73 patients with RET-rearranged lung cancers from multiple hospitals in China were registered. The majority of patients were female (56.5%), never smokers (62.9%) with NSCLCs (98.4%). 15 different molecular subtypes of infusion partners were identified in which twelve subtypes were not reported before. KIF5B-RET was the most common (51.6%) followed by CCDC8-RET (25.8%). Two patients coexist with ALK fusion, one patient with EGFR mutation, and one patient with C-MET amplification. Median OS was 20.8m (95%CI 14.9-96.4) for 46 stage IV NSCLCs. Median PFS was 7.0m (95%CI 2.7-11.7) in patients who received 1st-line treatment including chemotherapy and multi-targeted kinase inhibitors. Patients with CNS (N=14, 30.4%) had significantly shorter PFS with those without CNS (N=32, 69.6%) (4.4m vs 9.1m; p=0.04, HR 2.343[1.040-5.279]). There was no statistically significant difference in PFS in terms of upstream fusion partners (KIF5B v other partner) (p=0.059). Besides, sixteen patients received one or more lines multi-targeted kinase inhibitors: cabozantinib (fourteen patients), vandetanib (two patients) and anlotinib (three patients). The median line of systemic therapy of the first RET TKI administered was as second line (range, first to third line). The median PFS of multi-targeted kinase inhibitor therapy in patients with CNS was 9.0m (95%CI 2.5-15.5m).

      Conclusion

      This is the first real-world study reporting clinical outcomes of Chinese RET-rearranged advanced NSCLC patients by now, which included the most samples, either. Most patients received chemotherapy with unfavorable survival, although several patients may benefit more from available multi-targeted kinase inhibitors. CNS is an important risk factor whereas upstream fusion partners are not. More and novel targeted therapies for RET-rearranged patients are urgently needed in China.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.